Editorial
Neurological complications of anti-PD-1 antibodies: shall we be more concerned?
Translational Cancer Research
2018;
7
(Suppl 4)
:S436-S438
.
(26 April 2018)
ZATT, TDP2, and SUMO2: breaking the tie that binds TOP2 to DNA
Translational Cancer Research
2018;
7
(Suppl 4)
:S439-S444
.
(26 April 2018)
Evolutionary acquired robustness and vulnerability in cancer genome: negligible negative selection in carcinogenesis
Translational Cancer Research
2018;
7
(Suppl 4)
:S445-S448
.
(26 April 2018)
Fibroblast growth factor signaling as a bypass mechanism of the androgen receptor pathway: new perspectives for castrationresistant prostate cancer
Translational Cancer Research
2018;
7
(Suppl 4)
:S449-S452
.
(26 April 2018)
PD-1 in cancer: Dr. Jekyll and Mr. Hyde
Translational Cancer Research
2018;
7
(Suppl 4)
:S453-S456
.
(26 April 2018)
Myc and Ras, the Bonnie and Clyde of immune evasion
Translational Cancer Research
2018;
7
(Suppl 4)
:S457-S459
.
(26 April 2018)
Targeting HSP90 in malignant gliomas: onalespib as a potential therapeutic
Translational Cancer Research
2018;
7
(Suppl 4)
:S460-S462
.
(26 April 2018)
The emerging landscape of lncRNAs in diabetic nephropathy
Translational Cancer Research
2018;
7
(Suppl 4)
:S463-S465
.
(26 April 2018)
A human mutated gene is guillotining spermatozoa
Translational Cancer Research
2018;
7
(Suppl 4)
:S466-S468
.
(26 April 2018)
Hypofractionated whole breast irradiation is cost-effective—but is that enough to change practice?
Translational Cancer Research
2018;
7
(Suppl 4)
:S469-S472
.
(26 April 2018)
Adjuvant chemotherapy in patients with newly diagnosed non-co-deleted anaplastic gliomas—a new standard
Translational Cancer Research
2018;
7
(Suppl 4)
:S473-S475
.
(26 April 2018)
Editorial: fate mapping of human glioblastoma reveals an invariant stem cell hierarchy
Translational Cancer Research
2018;
7
(Suppl 4)
:S476-S479
.
(26 April 2018)
Duloxetine for AI-associated joint pain in breast cancer patients
Translational Cancer Research
2018;
7
(Suppl 4)
:S480-S483
.
(26 April 2018)
Temozolomide—the jack of all gliomas? Reviewing the interim results of the CATNON trial for 1p/19q non-co-deleted anaplastic glioma
Translational Cancer Research
2018;
7
(Suppl 4)
:S484-S487
.
(26 April 2018)
When the inhibitor is turned into stimulator: novel aspects in T cell engineering
Translational Cancer Research
2018;
7
(Suppl 4)
:S488-S490
.
(26 April 2018)
There must be another way—disulfiram and cancer treatment: editorial on “Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4”
Translational Cancer Research
2018;
7
(Suppl 4)
:S491-S494
.
(26 April 2018)
Disulfiram combats cancer via crippling valosin-containing protein/p97 segregase adaptor NPL4
Translational Cancer Research
2018;
7
(Suppl 4)
:S495-S499
.
(26 April 2018)
How many pancreatic cysts are out there and how to best manage them?
Translational Cancer Research
2018;
7
(Suppl 4)
:S500-S505
.
(26 April 2018)
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma
Translational Cancer Research
2018;
7
(Suppl 4)
:S506-S509
.
(26 April 2018)
Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma
Translational Cancer Research
2018;
7
(Suppl 4)
:S510-S513
.
(26 April 2018)
Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer
Translational Cancer Research
2018;
7
(Suppl 4)
:S514-S518
.
(26 April 2018)
Role of enhancer activation in pancreatic cancer metastasis
Translational Cancer Research
2018;
7
(Suppl 4)
:S519-S520
.
(26 April 2018)
Circular RNA FBXW7: implication in glioma tumorigenesis
Translational Cancer Research
2018;
7
(Suppl 4)
:S521-S524
.
(26 April 2018)
Improving hormonal therapy: to extend, to intermit, or to readjust expectations?
Translational Cancer Research
2018;
7
(Suppl 4)
:S525-S527
.
(26 April 2018)
Letter to the Editor
Is there still room for anti-angiogenic agents in small cell lung cancer?
Translational Cancer Research
2018;
7
(Suppl 4)
:S528-S529
.
(26 April 2018)
Perspective
PD-1/PD-L1 pathway inhibition to restore effector functions in exhausted CD8+ T cells: chances, limitations and potential risks
Translational Cancer Research
2018;
7
(Suppl 4)
:S530-S537
.
(26 April 2018)
Disclosure:
This supplement was published without any sponsorship or funding.
